Education
About Us
Working with TipRanks
Follow Us
Relay Therapeutics (RLAY)
NASDAQ:RLAY
RLAY Stock Chart & Stats
$8.56
>-$0.01(-0.22%)
At close: 4:00 PM EST
$8.56
>-$0.01(-0.22%)
Day’s Range― - ―
52-Week Range$1.78 - $9.04
Previous CloseN/A
Volume391.09K
Average Volume (3M)2.20M
Market Cap
$1.48B
Enterprise Value$336.77M
Total Cash (Recent Filing)$596.43M
Total Debt (Recent Filing)$33.33M
Price to Earnings (P/E)―
Beta1.91
Next Earnings
Feb 19, 2026EPS Estimate
-0.4Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.43
Shares Outstanding173,322,390
10 Day Avg. Volume2,735,039
30 Day Avg. Volume2,201,478
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)0.76
Price to Sales (P/S)58.82
P/FCF Ratio-2.34
Enterprise Value/Market Cap0.23
Enterprise Value/Revenue40.30
Enterprise Value/Gross Profit44.27
Enterprise Value/Ebitda-1.06
Forecast
1Y Price Target
$14.75Price Target Upside72.31% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-1.73
Revenue Forecast (FY)$12.81M
Bulls Say, Bears Say
Bulls Say
Financial StabilityRelay ended 3Q25 with $596.4M in cash, which should span several key data catalysts, since these resources are expected to provide an operational runway into 2029.
Product DevelopmentManagement is advancing triplet cohorts and exploring additional combinations to secure a favorable position for RLY-2608 in the treatment landscape for metastatic breast cancer.
Trial ProgressThe Ph3 ReDiscover-2 trial is continuing to enroll with optimistic expectations due to robust data showing significant results.
Bears Say
Expense OverrunR&D and SG&A expenses were $68.3M and $12.1M, respectively, vs. our estimates of $58.8M and $14.4M.
Financial PerformanceRelay recorded a net loss of $0.43 per share, relatively in line with our original net loss estimate of $0.38 per share.
Trial DelaysThe primary completion of a key trial has been delayed from the end of 2025 to the second quarter of 2027.
Relay Therapeutics News
RLAY FAQ
What was Relay Therapeutics’s price range in the past 12 months?
Relay Therapeutics lowest stock price was $1.77 and its highest was $9.04 in the past 12 months.
What is Relay Therapeutics’s market cap?
Relay Therapeutics’s market cap is $1.48B.
When is Relay Therapeutics’s upcoming earnings report date?
Relay Therapeutics’s upcoming earnings report date is Feb 19, 2026 which is in 52 days.
How were Relay Therapeutics’s earnings last quarter?
Relay Therapeutics released its earnings results on Nov 06, 2025. The company reported -$0.43 earnings per share for the quarter, missing the consensus estimate of -$0.415 by -$0.015.
Is Relay Therapeutics overvalued?
According to Wall Street analysts Relay Therapeutics’s price is currently Undervalued.
Does Relay Therapeutics pay dividends?
Relay Therapeutics does not currently pay dividends.
What is Relay Therapeutics’s EPS estimate?
Relay Therapeutics’s EPS estimate is -0.4.
How many shares outstanding does Relay Therapeutics have?
Relay Therapeutics has 173,322,390 shares outstanding.
What happened to Relay Therapeutics’s price movement after its last earnings report?
Relay Therapeutics reported an EPS of -$0.43 in its last earnings report, missing expectations of -$0.415. Following the earnings report the stock price went down -7.351%.
Which hedge fund is a major shareholder of Relay Therapeutics?
Currently, no hedge funds are holding shares in RLAY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Relay Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$14.75 (72.31% Upside)
$14.75 (72.31% Upside)
Blogger Sentiment
Bullish
RLAY Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 292.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.9%
Last 30 Days ▲ 12.2%
Last 30 Days ▲ 12.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
92.35%
12-Months-Change
Fundamentals
Return on Equity
-41.14%
Trailing 12-Months
Asset Growth
-27.97%
Trailing 12-Months
Company Description
Relay Therapeutics
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and RLY-1971, an oral small molecule inhibitor of protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2 that is in Phase 1 trial in patients with advanced solid tumors. It has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of RLY-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
RLAY Stock 12 Month Forecast
Average Price Target
$14.75
▲(72.31% Upside)
Technical Analysis
Ownership Overview
2.57% Insiders
9.93% Mutual Funds
53.98% Other Institutional Investors
22.21% Public Companies and
Individual Investors